Results
The search strategy identified 237 new references since the 2006 review, 1 of which 2 new studies were identified that met the inclusion criteria. These were added to 5 studies from the existing review, resulting in 7 total studies comprising 622 participants. Six studies were conducted with adults and one study was conducted with pediatric patients. Verapamil was used in all studies, although one study had both a verapamil and a diltiazem treatment arm.
There was no difference in the rates of reversion to sinus rhythm between adenosine and calcium channel antagonists (Table) . Three trials reported on hypotension, with only one case identified in the calcium channel antagonist group. Four studies, comprising 442 patients, evaluated time to reversion, with a significantly reduced time in the adenosine group (mean¼44 seconds) compared with the calcium channel antagonist group (mean¼394 seconds). However, because of heterogeneity between studies assessing time to reversion, meta-analysis was not possible. There was no significant difference in relapse rates between adenosine and calcium channel antagonists. Studies were at overall unclear risk of bias except for blinding, for which all studies were at high risk. 5 A modification of the Valsalva maneuver, in which the patient is placed in the supine position with the legs elevated, has been found to be more effective, with a success rate of 43%. 6 For patients in whom vagal maneuvers are unsuccessful, atrioventricular nodal-blocking agents are recommended.
7
The 2015 American Heart Association guidelines for the treatment of supraventricular tachycardia recommend adenosine as a first-line medication, followed by calcium channel antagonists if adenosine is contraindicated or fails to terminate the supraventricular tachycardia episode. 7 Adenosine is not recommended for atrial dysrhythmias (eg, atrial fibrillation, atrial flutter) and neither agent should be used when Wolff-Parkinson-White's syndrome is suspected.
This study found that adenosine and calcium channel antagonists had similar efficacy and adverse events for the treatment of supraventricular tachycardia. However, it is important to consider several limitations with respect to this review. First, there were a limited number of studies and the overall sample size was relatively small. This is especially important with respect to the endpoint of hypotension, of which there were only 306 patients assessed and low overall rates in both groups. Additionally, most adverse events were not defined a priori and many were not explicitly quantified, which may have led to underreporting of events. Moreover, the included publications varied in the dosing of both adenosine and verapamil between studies. Because all of the studies used verapamil, there were few studies examining the comparative effectiveness of diltiazem. However, diltiazem has been suggested to have decreased atrioventricular nodal blockade compared with verapamil, so it is unlikely that different outcomes would be noted with this medication. 8 Data involving pediatric patients was also limited. Finally, no studies assessed patient satisfaction, which is an important consideration in the choice of agents.
Based on the current evidence, both medications have similar reversion rates although adenosine has faster results. Future studies should assess adverse events by using strict, predefined criteria and determine which agent patients prefer. 
